IsoTis OrthoBiologics, Alphatec Spine sign private-label deal for DynaGraft II, OrthoBlast II

By E. Janene Geiss

Philadelphia, July 11 - IsoTis SA announced Tuesday it has entered into a non-exclusive private label agreement for its demineralized first-generation bone matrix products DynaGraft II and OrthoBlast II with Alphatec Holdings, Inc.

Financial details were not disclosed, according to a company news release.

The company said that in its last reported period, private label sales accounted for about 10% of global sales while sales of its Accell product line increased 39% to nearly two-thirds of sales in the United States.

IsoTis said it expects Alphatec, with its recent growth in the U.S. spine market, will be a significant contributor to the private label efforts.

IsoTis OrthoBiologics, based in Irvine, Calif., develops and manufactures natural and synthetic bone graft substitutes.

Alphatec Spine, a wholly owned subsidiary of Carlsbad, Calif.-based Alphatec Holdings, Inc., is a medical device company focused on surgical treatment of spine disorders.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.